Evidence map›Paper›PMID 29771781›Full record

ArticleJournal of acquired immune deficiency syndromes (1999)2018

Lack of Virological Suppression Among Young HIV-Positive Adults in Botswana.

Vlad Novitsky, Tendani Gaolathe, Mompati Mmalane, Sikhulile Moyo, Unoda Chakalisa, Etienne Kadima Yankinda, Tafireyi Marukutira, Molly Pretorius Holme, Tumalano Sekoto, Simani Gaseitsiwe and 15 more

Registry-linked trialAbstract read
In one paragraph

Article in Journal of acquired immune deficiency syndromes (1999), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01965470 (Botswana Combination Prevention Project), which is not on this map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01965470 phase4completednot on this map

Botswana Combination Prevention Project: -Evaluation Protocol (Protocol #1): Research Design and Impact Evaluation -Closed Clinical Cohort Protocol (Protocol #3) Implementation, Monitoring and Evaluation of Combination HIV Prevention Interventions in Rural and Peri-Urban Communities in Botswana

TypeinterventionalSponsorCenters for Disease Control and PreventionRan2013 to 2018ConditionsHIVArmsCombination Prevention, Enhanced Care
3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Vlad NovitskyBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Tendani GaolatheBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Mompati MmalaneBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Sikhulile MoyoBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Unoda ChakalisaBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Etienne Kadima YankindaBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Tafireyi MarukutiraDivision of Global HIV/AIDS, Centers for Disease Control and Prevention, Gaborone, Botswana.
Molly Pretorius HolmeDepartment of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA.
Tumalano SekotoBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Simani GaseitsiweBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Rosemary MusondaBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Erik van WidenfeltBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Kathleen M PowisBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Nealia KhanDepartment of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA.
Scott Dryden-PetersonBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Kara BennettBennett Statistical Consulting, Inc, Ballston Lake, NY.
Kathleen E WirthDepartment of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA.
Eric Tchetgen TchetgenBiostatistics, Harvard T.H. Chan School of Public Health, Boston, MA.
Pam BachanasDivision of Global HIV/AIDS, Centers for Disease Control and Prevention, Atlanta, GA.
Lisa A MillsDivision of Global HIV/AIDS, Centers for Disease Control and Prevention, Gaborone, Botswana.
Refeletswe LebelonyaneMinistry of Health and Wellness, Republic of Botswana, Gaborone, Botswana.
Shenaaz El-HalabiMinistry of Health and Wellness, Republic of Botswana, Gaborone, Botswana.
Joseph MakhemaBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Shahin LockmanBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
M EssexBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana.

Funding

Partnership for Global Health Research Training Program (Renewal)-Supplement for OBSSR, NCI, NCI-AIDS and NIDCDD43TW010543 · FIC · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Wafaie W Fawzi, DAVIDSON HOWES HAMER · 2017 to 2026
$12.1M
CGH CDC HHS U01 GH000447CGH CDC HHS U2G GH001911FIC NIH HHS D43 TW010543PEPFARWellcome Trust 107752/Z/15/Z
6 · The paper itself

Abstract

backgroundHIV-1 RNA load is the best biological predictor of HIV transmission and treatment response. The rate of virologic suppression among key subpopulations can guide HIV prevention programs.

methodsThe Botswana Combination Prevention Project performed a population-based household survey among adults in 30 communities in Botswana. Data collected included knowledge of HIV-positive status, antiretroviral therapy (ART) coverage, and virologic suppression (HIV-1 RNA ≤400 copies per milliliter). Individuals aged 16-29 years were considered young adults.

resultsAmong 552 young people living with HIV enrolled with RNA load data and ART status available, 51% (n = 279) had undetectable HIV-1 RNA, including 54% of young women and 32% of young men [sex prevalence ratio (PR): 0.53; 95% confidence interval (CI): 0.43 to 0.80; P < 0.001]. Compared with older adults (30-64 years old), young HIV-infected adults were significantly less likely to have undetectable HIV-1 RNA (PR: 0.65; 95% CI: 0.59 to 0.70; P < 0.0001), including both men (PR: 0.43; 95% CI: 0.34 to 0.56; P < 0.0001) and women (PR: 0.67; 95% CI: 0.62 to 0.74; P < 0.0001). Among a subset of people living with HIV receiving ART, young adults also were less likely to have undetectable HIV-1 RNA load than older adults (PR: 0.93; 95% CI: 0.90 to 0.95; P = <0.0001). Analysis of the care continuum revealed that inferior HIV diagnosis and suboptimal linkage to care are the primary reasons for low virologic suppression among young adults.

conclusionsYoung adults in Botswana are significantly less likely to have undetectable HIV-1 RNA load compared with older adults. In the era of broad scale-up of ART, interventions able to diagnose young adults living with HIV and link them to effective therapy are urgently needed.

Indexed as

Viral LoadAdolescentAdultAnti-HIV AgentsBotswanaContinuity of Patient CareFemaleHIV-1HIV InfectionsHumansMaleMiddle AgedRNA, ViralSurveys and QuestionnairesYoung AdultAnti-HIV AgentsRNA, Viral

Identifiers

PMID29771781
PMCPMC6069598

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.